EUCTR2006-004553-17-AT进行中（未招募）不适用
A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR IN COMBINATION WITH PREDNISONE TO STUDY FURTHER IN SUBJECTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.=18 years old at time of signed informed consent.
- •2.Diagnosed with myelofibrosis requiring therapy including myelofibrosis with myeloid metaplasia.
- •3.Eligibility is based on local review of bone marrow aspirate and biopsy.
- •4.Screening total Hb level <10g/dL or transfusion-dependent anemia defined as per IWG criteria.
- •5.Adequate organ function as demonstrated by the following = 14 days prior to starting study drug:
- •ALT (SGPT)/AST (SGOT) =3x upper limit of normal (ULN) [unless treating physician believes this is due to extramedullary hematopoiesis].
- •Total Bilirubin <3x ULN or Direct Bilirubin <2x ULN
- •Serum creatinine =2.0 mg/dL
- •Absolute neutrophil count =1,000/µL (=1 x 109/L)
- •Platelet count =50,000 /µL (=50 x 109/L)
- •6.Willing to receive transfusion of blood products
- •7.ECOG performance status of 0-2 at screening.
- •8.Able to adhere to study visit schedule and other protocol requirements.
- •9.No active malignancies with exception of controlled prostate cancer , basal cell or squamous cell carcinoma of the skin, or carcinoma in situ” of the cervix or breast.
- •10.Females of childbearing potential (FCBP) must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to the study:1) for at least 28 days before starting study drug; 2)while participating in study; 3) for at least 28 days after discontinuation from study. The 2 methods of reliable contraception must include 1 highly effective method (ie intrauterine device [IUD], hormonal [birth control pills, injections, or implants], tubal ligation, or partner’s vasectomy) and 1 additional effective (barrier) method (ie latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
- •Before starting study drug:
- •Female Subjects:
- •FCBP must have 2 negative pregnancy tests (sensitivity of at least 50mIU/mL) prior to starting study drug, the first of which must be performed within 10-14 days prior to start of study drug and the second performed within 24 hours prior to start of study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
- •Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure.
- •Must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from study.
- •Male Subjects:
- •Must agree to use a latex condom during sexual contact with FCBP while participating in study and for at least 28 days following discontinuation from study even if he has undergone a successful vasectomy.
- •Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure.
- •Must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from study.
- •During study participation and for 28 days following discontinuation from the study:
- •All Subjects:
- •No more than a 28-day supply of study drug will be dispensed at a time.
- •Female Subjects:
- •FCBP with regular cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study discontinuation, and at day 28 following discontinuation from study. If menstrual cycles are irregular,
排除标准
- •1.Known positive status for HIV, hepatitis B carrier, or active hepatitis C infection.
- •2.Previous untoward reaction to corticosteroid (specifically, prednisone) therapy that was severe enough, in the opinion of the treating physician, to preclude study participation.
- •3.The use of any growth factors, cytotoxic chemotherapeutic agents (e.g. hydroxyurea and anagrelide), corticosteroids, or experimental drug or therapy within a minimum of 28 days of starting CC-4047 and/or lack of recovery from all toxicity from previous therapy to grade 1 or better (e.g. alpha interferon may require 84 days or longer for washout).
- •4.Prior therapy with CC-4047, lenalidomide or thalidomide for MMM. (Prior prednisone use as a therapy for MMM is allowed, but not within 28 days of starting CC-4047).
- •5.History of deep vein thrombosis or pulmonary embolism within one year of starting study medication.
- •6.Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •7.Pregnant or lactating females.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR IN COMBINATION WITH PREDNISONE TO STUDY FURTHER IN SUBJECTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA - NDMYELOFIBROSIS WITH MYELOID METAPLASIAMedDRA version: 9.1Level: LLTClassification code 10028537Term: MyelofibrosisEUCTR2006-004553-17-ITCelgene Corporation80
进行中（未招募）
不适用
A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR IN COMBINATION WITH PREDNISONE TO STUDY FURTHER IN SUBJECTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIAMyelofibrosis with myeloid metaplasiaMedDRA version: 9.1Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaEUCTR2006-004553-17-DECelgene Corporation80
进行中（未招募）
不适用
A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR IN COMBINATION WITH PREDNISONE TO STUDY FURTHER IN SUBJECTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIAMyelofibrosis with myeloid metaplasiaMedDRA version: 9.1Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaEUCTR2006-004553-17-GBCelgene Corporation80
进行中（未招募）
1 期
A Phase 2a, multi-center, prospective trial with random assignments to treatment Groups. The Trial is double-blind, vehicle controlled and dose ranging. The aim ist to evaluate the efficacy and safety of CB-03-01 solution for the Treatment with male pattern baldness.EUCTR2016-003733-23-DECassiopea S.p.A.400
进行中（未招募）
不适用
A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS)EUCTR2008-000349-68-GBPfizer Inc. 235 East 42nd Street, New York NY10017160